Stemline Therapeutics, Inc.
STML
STML was delisted on the 9th of June, 2020.
61 hedge funds and large institutions have $67.8M invested in Stemline Therapeutics, Inc. in 2016 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 18 increasing their positions, 17 reducing their positions, and 10 closing their positions.
43% more capital invested
Capital invested by funds: $47.5M → $67.8M (+$20.3M)
6% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 17
3% less funds holding
Funds holding: 63 → 61 (-2)
10% less first-time investments, than exits
New positions opened: 9 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Franklin Resources
San Mateo,
California
|
+$1.4M |
| 2 |
BFA
BlackRock Fund Advisors
San Francisco,
California
|
+$200K |
| 3 |
PAM
Paradigm Asset Management
New York
|
+$131K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$125K |
| 5 |
Dimensional Fund Advisors
Austin,
Texas
|
+$124K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
TimesSquare Capital Management
New York
|
-$1.36M |
| 2 |
Millennium Management
New York
|
-$697K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$210K |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
-$210K |
| 5 |
Renaissance Technologies
New York
|
-$165K |
STML Hedge Fund Activity: Q2 2016 in Review
61 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Stemline Therapeutics, Inc. (STML) for Q2 2016, worth a combined $67.8M — up 43% from $47.5M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of STML and 9 opened new positions — a net loss of 1 holder — while 17 trimmed existing stakes and 18 added.
The largest buyer was Franklin Resources, adding an estimated $1.4M. The largest seller was TimesSquare Capital Management, cutting an estimated $1.36M.
- 61 institutional investors held Stemline Therapeutics, Inc. (STML) as of Q2 2016, down from 63 in Q1 2016.
- Funds reported $67.8M of Stemline Therapeutics, Inc. stock for Q2 2016, up 43% quarter-over-quarter.
- 9 funds opened new Stemline Therapeutics, Inc. positions in Q2 2016 and 10 closed out, a net change of -1 holder.
- The largest Stemline Therapeutics, Inc. buyer in Q2 2016 was Franklin Resources, an estimated $1.4M added.
- The largest Stemline Therapeutics, Inc. seller in Q2 2016 was TimesSquare Capital Management, an estimated $1.36M sold.
Based on aggregated 13F filings for Q2 2016.